VBIV News and Press, VBI Vaccines Inc. From 04/02/24

2024-04-02 09:49:20 ET More on VBI Vaccines VBI signs deal to sell manufacturing capabilities, certain assets with Brii Biosciences Seeking Alpha’s Quant Rating on VBI Vaccines Historical earnings data for VBI Vaccines Financial information for VBI Vac...

VBI Vaccines and the Canadian government broaden scope of longstanding collaboration to accelerate development of VBI’s novel, mRNA-launched enveloped virus-like particle vaccine (“MLE”) technology platform The partnership will direct CAD$28 million of funding remaini...

GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...

Community Bancorp Inc Vermont (CMTV) is expected to report for Q4 2023 CISO Global, Inc (CISO) is expected to report for Q4 2023 TCTM Kids IT Education Inc. (TCTM) is expected to report for quarter end 2023-12-31 Generation Income Properties Inc. (GIPR) is expected to report for quart...

Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...

Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...

2024-02-14 08:56:13 ET More on VBI Vaccines Seeking Alpha’s Quant Rating on VBI Vaccines Historical earnings data for VBI Vaccines Financial information for VBI Vaccines Read the full article on Seeking Alpha For further details see: VBI si...

VBI to receive up to $33 million in consideration, subject to achievement of certain activities, for: VBI’s manufacturing capabilities and certain related assets at Rehovot manufacturing facility Intellectual property for VBI-2601, VBI’s hepatitis B immunotherapeutic candida...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherapeutic cand...

2023-11-14 16:43:56 ET More on VBI Vaccines VBI Vaccines gains after Phase 2 data for Hep B candidate Seeking Alpha’s Quant Rating on VBI Vaccines Historical earnings data for VBI Vaccines Financial information for VBI Vaccines For further deta...